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OBJECTIVEdBoth in vitro and in vivo studies indicate that metformin inhibits cancer cell
growth and reduces cancer risk. Recent epidemiological studies suggest that metformin therapy
may reduce the risks of cancer and overall cancer mortality among patients with type 2 diabetes.
However,dataonitseffectoncolorectalcancerarelimitedandinconsistent.Wethereforepooled
data currently available to examine the association between metformin therapy and colorectal
cancer among patients with type 2 diabetes.
RESEARCH DESIGN AND METHODSdThe PubMed and SciVerse Scopus databases
were searched to identify studies that examined the effect of metformin therapy on colorectal
cancer among patients with type 2 diabetes. Summary effect estimates were derived using a
random-effects meta-analysis model.
RESULTSdThe analysis included ﬁve studies comprising 108,161 patients with type 2 di-
abetes.Metformintreatmentwasassociatedwithasigniﬁcantlylowerriskofcolorectalneoplasm
(relative risk [RR] 0.63 [95% CI 0.50–0.79]; P , 0.001). After exclusion of one study that
investigatedcolorectaladenoma,theremainingfourstudiescomprised107,961diabeticpatients
and 589 incident colorectal cancer cases during follow-up. Metformin treatment was associated
with a signiﬁcantly lower risk of colorectal cancer (0.63 [0.47–0.84]; P = 0.002). There was no
evidenceforthepresenceofsigniﬁcantheterogeneitybetweentheﬁvestudies(Q=4.86,P=0.30;
I
2 = 18%).
CONCLUSIONSdFrom observational studies, metformin therapy appears to be associated
with a signiﬁcantly lower risk of colorectal cancer in patients with type 2 diabetes. Further
investigation is warranted.
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olorectal cancer is one of the most
frequent malignant tumors and a
leading cause of cancer-related
deathworldwide(1).Theincidenceofco-
lorectal cancer continues to increase in
economically transitioning countries
suchasAsia,EasternEurope,andselected
countriesinSouthAmerica(2,3),whereasa
declining trend has been noted in several
developed countries in recent years (1).
Type 2 diabetes is also a common
disease,and itiswellestablished that type
2 diabetes is associated with a higher risk
of colorectal cancer (4–8). Metformin is a
relative of isoamylene guanidine and has
been recommended as the initial glucose-
lowering therapy for diabetes. Emerging
evidence from both in vitro and in vivo
studies indicates that metformin may in-
hibit cancer cell growth and reduce can-
cer risks. Previous research suggests that
metformin may be involved in the tumor
suppressor pathway by indirectly activat-
ing AMP-activated protein kinase (9)d
a key sensor of cellular ATP and AMP
balancedand plays a role on activating
tumor suppressor genes, e.g., LKB1.S u b -
sequent in vitro studies have shown that
metformin inhibits cancer cell prolifera-
tion (10,11) and selectively kills cancer
stem cells (12). Animal experiments con-
cur with these ﬁndings. Rodent models
have shown that metforminsuppressesco-
lonic epithelial proliferation and colorectal
aberrant cryptfociformation(13,14).Sim-
ilarly, animal models of colon cancer have
shownthatmetformininhibitscolon carci-
noma growth (11,15).Giventheseencour-
aging ﬁndings, interest has arisen that
metformin could potentially serve as a
newantineoplasmdrugtopreventcolorec-
tal cancer.
Results from preliminary studies con-
ducted in humans are encouraging. In a
short-termrandomizedclinicaltrialamong
nondiabetic patients with rectal aberrant
crypt foci, a signiﬁcant decrease in the
mean number of aberrant crypt foci was
observed after metformin treatment for
1 month as compared with no signiﬁcant
changes in the control group (16). Find-
ings from several epidemiological studies
also support an antineoplastic role of met-
formin on cancer risks (17,18). If metfor-
min therapy ultimately proves effective on
reducing the risk of colorectal cancer, it
would likely be recommended for the
overwhelming majority of diabetes pa-
tients for both blood glucose control and
cancer prevention. Nonetheless, despite
accumulating evidence from population
studies that indicate a lower risk of can-
cer at large with metformin therapy
(17,19,20), data on its effect on colorectal
cancer are limited and inconsistent.
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META-ANALYSISAccordingly,weperformedameta-analysis
topoolstudiescurrentlyavailabletoexam-
ine the effect of metformin treatment on
colorectal cancer risk among patients with
type 2 diabetes.
RESEARCH DESIGN AND
METHODS
Study selection
A comprehensive literature search was
performed using the PubMed (January
1966–March 2011) and SciVerse Scopus
databases. Keywords for searching in-
cluded metformin, biguanides, cancer,
neoplasms, colorectal cancer, colon can-
cer, rectal cancer, and bowel cancer. We
selected studies that investigated the ef-
fect of metformin on colorectal cancer or
bowel cancer (ICD-9 153–154, ICD-10
C18–C20) in patients with type 2 diabe-
tes. The search was restricted to studies
conducted in humans. Because colorectal
cancer develops from precursor lesions
(21), we also included studies that inves-
tigated the association between metfor-
min therapy and colorectal adenoma.
We required either information on sam-
ple size, effect estimate, and correspond-
ing 95% CI or published results in which
these parameters could be derived. Refer-
ences from recent review articles were also
checked for relevant articles. The most
complete or more recent publications
weregivenprecedenceifthereweremul-
tiple publications from the same study.
Data extraction and statistical
analyses
Two members independently reviewed
titles and abstracts of all identiﬁed cita-
tions. The full text of any article that was
deemed potentially eligible was evaluated
forthedecisiononinclusionorexclusion.
Figure 1 depicts the process of study se-
lection. The results of the data extraction
were summarized in a structured table to
explore the variation in study design, re-
gionofstudy, sourcepopulation,number
of participants, length of follow-up (if ap-
plicable), and control for confounding.
The relative risk (RR) was used as the
common measure of association across
studies. Odds ratios were assumed to
be a reasonable estimate for relative risks
for the present study. Forest plots were
used to compare results across studies.
For those studies consisting of multiple
pairwise comparisons, we pooled the ef-
fect estimates with an inverse variance
weight and used the combined estimate
for that study. The resulting variance of
thepooled estimate does notallow forthe
correlationbetweenthemultipleeffectes-
timates in the same study and can be ei-
ther too large or too small, depending on
the correlation. Thus, to examine the in-
ﬂuence of the correlation, we performed
sensitivity analysesby including onepair-
wise comparison at a time when recalcu-
lating the summary RRs. The pooled RR
was derived by averaging per-study nat-
ural logarithmic RRs weighted by the in-
verses of their variances. We used the
DerSimonian and Laird random-effects
models to incorporate between-study var-
iability and to report pooled effect esti-
mates (22).
As part of sensitivity analyses, we
excluded one small study (23) that inves-
tigated the association between metfor-
min therapy and colorectal adenoma
to examine its inﬂuence on the summary
effect estimate. To assess for heterogene-
ity between studies, we calculated the
Cochran Q statistic with signiﬁcance level
of P , 0.10 (24). P values were obtained
by comparing the statistic with a x
2 dis-
tribution with k21 degrees of freedom
(where k is the number of studies). Be-
cause the power of the Q test is low to de-
tect heterogeneity in circumstances of
small number of studies, we also calcu-
lated the I
2 statistic, which quantiﬁes the
percentageof total variation across studies
that is due to heterogeneity rather than
chance (25). An I
2 value of ,50% was
considered low heterogeneity. Publica-
tion bias was assessed by visually ex-
amining a funnel plot and performing
t h eB e g gt e s t( 2 6 ) .At w o - t a i l e dP value
,0.05 was considered signiﬁcant for sta-
tistical tests for metformin effects. All
analyses were performed using Stata ver-
sion 10.0 (StataCorp, College Station,
Texas).
RESULTSdFive relevant studies were
retrieved, including two case-control stud-
ies (6,23) and three retrospective cohort
studies (17,18,27), comprising a total of
108,161 patients with type 2 diabetes.
Figure 1dFlowchart of study selection process.
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Metformin and colorectal cancerInformation on region, source population,
and confounding adjustment is presented
in Table 1. One study was based in China
(27), one study in Korea (23), and three
studiesinthe U.K.(6,17,18). Fourstudies
investigated the association between
metformin therapy and colorectal cancer
(6,17,18,27), and the other one inves-
tigated the association for colorectal
adenoma (23).
Compared with nonmetformin treat-
ment, metformin was associated with a sig-
niﬁcantlylower risk ofcolorectalneoplasm
among patients with type 2 diabetes
(pooled RR 0.63 [95% CI 0.50–0.79];
P , 0.001). Figure 2 shows the estimated
RR and 95% CI for each individual study
comparing metformin with nonmetfor-
min treatment. There was no evidence for
the presence of signiﬁcant heterogeneity
between the ﬁve studies (Q =4 . 8 6 ,P =
0.30; I
2 = 18%). There was also no evi-
denceofpublicationbiasfromthefunnel
plot examination or the Begg test (data
not shown).
After exclusion of one small case-
control study that investigated colorectal
adenoma (23), the database consisted
of three retrospective cohort studies
(17,18,27) and one nested case-control
study (6). Among a total of 107,961 pa-
tients with type 2 diabetes, 589 colorectal
cancer events were documented over
follow-up.Metformintherapywasassoci-
ated with a lower risk of colorectal cancer
(RR0.63[95%CI0.47–0.84];P=0.002).
Thus, exclusion of the small case-control
study had no appreciable effects on the
overall results. Figure 3 shows the esti-
mated RR and 95% CI for each individual
study comparing metformin with non-
metformin treatment. Again, there was
noevidenceforthepresenceofsigniﬁcant
heterogeneity between the four studies
(Q =4 . 7 5 ,P =0 . 1 9 ;I
2 = 37%). Although
the results showed a reduction of similar
magnitude in the risk of colorectal can-
cer with metformin treatment when
compared with two other treatment
groups (18), we performed sensitivity
analysis by including one of the two
effect estimates at a time. The results
did not change materially after exclud-
ingeithercomparison(datanotshown).
CONCLUSIONSdIn this study, we
pooled all studies currently available and
evaluated the association between met-
formin and colorectal cancer risk among
patients with type 2 diabetes. The results
indicate that metformin therapy was as-
sociated with an estimated reduction of
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Zhang and Associates37% in the risk of colorectal cancer
among patients with type 2 diabetes.
The effect estimates were homogeneous
across studies of different designs, in-
cluding retrospective cohort and nested
case-control studies. The multiple sen-
sitivity analyses showed that the results
were robust.
Other lines of evidence support the
antineoplastic role of metformin on colo-
rectal cancer. In vitro studies have shown
that metformin inhibits the proliferation of
colorectal cancer cells (28). In vivo studies
have demonstrated that metformin delays
tumor onset in mouse models for p53 mu-
tant colon cancer (11). Another animal
modelofcoloncancerhasshownthatmet-
formin inhibits colon carcinoma growth
stimulated by a high-energy diet (15).
Two animal models of colorectal aberrant
crypt foci showed that metformin signiﬁ-
cantly suppresses colonic epithelial prolif-
erationbyinhibitingthemammaliantarget
of rapamycin pathway (13,14). A ran-
domized clinical trial among nondiabetic
patients with a follow-up of 1 month dem-
onstratedthatthenumberofaberrantcrypt
foci decreased signiﬁcantly in the metfor-
min group (8.78 before treatment vs. 5.11
at 1 month follow-up, P = 0.01) but not in
the nonmetformin group (7.23 before
treatment vs. 7.56 at 1 month follow-up,
P = 0.61) (16). These ﬁndings are encour-
aging as metformin, in addition to its ap-
parent anticancer properties, has the
advantage of high tolerance, affordability,
and good compatibility with other hypo-
glycemic agents.
The mechanisms underlying this an-
tineoplastic potential of metformin for
colorectalcanceraremanifoldand notyet
completely understood. A previous study
showed that metformin indirectly acti-
vates AMP-activated protein kinase (9),
which induces glucose uptake in muscles
(29). Because AMP-activated protein ki-
nase is also activated by the product of
the Peutz-Jegher tumor suppressor gene
LKB1(30),itmayplayaroleinsuppressing
colorectal cancer development (31,32).
This relationship between metformin and
LKB1 represents one of the more plausible
mechanisms for a potential protective role
ofmetforminagainstcolorectalcancer.An-
other possible mechanism is amelioration
of endogenous hyperinsulinemia by use of
metformin therapy (33,34). Insulin stimu-
latescellularproliferation,andmultiplesig-
naling pathways are activated after insulin
receptors or insulin-like growth factor re-
ceptors interact with their ligands (35,36).
Metformin therapy decreases levels of
insulin-like growth factors and insulin in
circulation which, in turn, may reduce the
risk of colorectal cancer. Other possible
mechanisms underlying this potential anti-
tumor effect could be antagonizing obesity
(37), anti-inﬂammatory effects (38), p-53
activation (11), downregulation of cyclin
D1 (39), and killing of cancer stem cells
(12). Further studies investigating potential
underlying mechanisms are needed.
Our meta-analysis pooled all pub-
lished data currently available and pro-
vided strong evidence of antineoplastic
effect on colorectal cancer with metfor-
min treatment. However, caution is
needed when interpreting these results.
Figure 2dPooled estimate of relative risk and 95% CIs of colorectal neoplasm associated with
metformin therapy based on ﬁve studies comprising 108,161 patients with type 2 diabetes.
Squares indicate relative risk in each study. The square size is proportional to the weight of the
corresponding study in the meta-analysis; the length of horizontal lines represents the 95% CI.
The unshaded diamond indicates the pooled relative risk and 95% CI.
Figure 3dPooled estimate of relative risk and 95% CIs of colorectal cancer associated with
metformin therapy based on four studies comprising 107,961 diabetic patients and 589 incident
colorectal cancer cases. Squares indicate relative risk in each study. The square size is pro-
portional to the weight of the corresponding study in the meta-analysis; the length of horizontal
linesrepresentsthe95%CI.Theunshadeddiamondindicatesthepooledrelative riskand95%CI.
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Metformin and colorectal cancerInformation on metformin use was col-
lected retrospectively in all of the included
observational (uncontrolled) studies. Most
of the included studies were based on
historical medical data or insurance data
thatwerenotspeciﬁcallydesignedtoassess
the effectofmetformin therapy oncolorec-
tal cancer. Details on dose, duration, var-
iation over time for metformin treatment,
and other adjunctive therapy were incom-
plete. The possibility of immortal bias was
not completely ruled out in some included
studies. Most of the included studies did
not collect or analyze data on pathological
type or site of colorectal cancer. In the
present study, metformin therapy was
compared with other hypoglycemic ther-
apies, including insulin, sulfonylureas,
thiazolidinediones, or other oral medi-
cines. It should be noted that insulin and
insulin analogs have been reported to be
associated with a higher risk of colorectal
cancer (6,7). The observed apparent ben-
eﬁcialeffectofmetformincouldthusbean
overestimate partly due to the potential
hazardous effect associated with other hy-
poglycemic agents in the reference group.
On the other hand, metformin receivers
were reported to be more likely to receive
lower endoscopy (40), which could lead
to early detection of colorectal cancer in
metformin receivers and bias the effect es-
timate toward the null (i.e., no anticancer
effect). Finally, the possibility of publica-
tion bias cannot be ruled out although we
foundnoevidenceofthisthroughthefun-
nel plot examination and the Begg test.
In conclusion, our meta-analysis sug-
geststhatmetformintreatmentappearsto
beassociatedwithasigniﬁcantlylowerrisk
of colorectal cancer in patients with type 2
diabetes.Furtherinvestigationiswarranted.
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